EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

May 21, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
Advanced Solid Malignancy
Interventions
DRUG

Module 1 (GRWD5769 on its own as monotherapy)

"Module 1 will initially be conducted in 4 study parts:~Part A: Monotherapy dose escalation (where the safety of increasing doses of GRWD5769 will initially be assessed in a small group of patients, overseen by a safety review committee)~Part B: (Optional) Monotherapy dose expansion part (to look at the effect of GRWD5769 on the body, and of the body on GRWD5769, at particular dose levels to include evaluation of biopsies of tumour tissue)~Part C: (Optional) Intra-patient dose escalation (where a patient may receive three different GRWD5769 doses so that blood levels at each dose can be measured in an individual)~Part D: Monotherapy dose expansion group(s) (where a dose of GRWD5769 may be chosen to be evaluated in specific types of cancer)"

DRUG

Module 2 (GRWD5769 in combination with cemiplimab, administered IV)

"Module 2 will initially be conducted as 3 study parts, similar to those above, but looking at GRWD5769 when given in combination with cemiplimab:~Part A: Combination therapy dose escalation (like Module 1 Part A)~Part B: (Optional) Combination therapy dose expansion part (like Module 1 Part B)~Part C: Combination therapy dose expansion group(s) (where a dose of GRWD5769 given with cemiplimab will be evaluated in specific types of cancer)"

Trial Locations (29)

Unknown

RECRUITING

GenesisCare Research, Adelaide

RECRUITING

Southern Oncology Clinical Research Unit (SOCRU), Bedford Park

RECRUITING

Blacktown Hospital, Blacktown

RECRUITING

Kinghorn Cancer Centre (KCC), Darlinghurst

RECRUITING

Austin Health, Heidelberg

RECRUITING

Alfred Health, Melbourne

RECRUITING

Mater Research, South Brisbane

RECRUITING

Cancer Care Wollongong, Wollongong

RECRUITING

Centre Léon Bérard, Lyon

RECRUITING

Institut Paoli-Calmettes, Marseille

RECRUITING

Centre Eugène Marquis, Rennes

RECRUITING

Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain

NOT_YET_RECRUITING

ICANS - Institut de Cancérologie Strasbourg, Strasbourg

RECRUITING

IUCT Oncopole - Institut Claudius Regaud, Toulouse

RECRUITING

Institut Gustave Roussy, Villejuif

RECRUITING

Hospital Universitario Vall d'Hebrón (VHIO), Barcelona

RECRUITING

START Barcelona - Hospital HM Nou Delfos, Barcelona

RECRUITING

Clinica Universitaria de Navarra Madrid, Madrid

RECRUITING

START Madrid - Centro Integral Oncológico Clara Campal (HM CIOCC), Madrid

RECRUITING

START Madrid - Hospital Universitario Fundacion Jimenez Diaz, Madrid

RECRUITING

Hospital Universitario Virgen de la Victoria, Málaga

RECRUITING

Clinica Universitaria de Navarra Pamplona, Pamplona

RECRUITING

INCLIVA-Hospital Clínico Universitario de Valencia, Valencia

RECRUITING

Western General Hospital, Edinburgh

RECRUITING

Clatterbridge Cancer Centre, Liverpool

RECRUITING

Hammersmith Hospitals NHS Trust, London

RECRUITING

Royal Free Hospital, London

RECRUITING

Christie NHS Foundation Trust, Manchester

RECRUITING

Newcastle Upon Tyne Hospital, Newcastle

Sponsors
All Listed Sponsors
lead

Grey Wolf Therapeutics

OTHER

NCT06923761 - EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) | Biotech Hunter | Biotech Hunter